- Home
- DH vs PALI Comparison
DH vs PALI Comparison
Compare DH & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DH | PALI |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 240.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DH | PALI |
|---|---|---|
| Price | $1.12 | $1.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.43 | ★ $13.00 |
| AVG Volume (30 Days) | 392.1K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.28 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $0.97 | $0.55 |
| 52 Week High | $4.70 | $2.64 |
Technical Indicators
Market Signals| Indicator | DH | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 57.67 |
| Support Level | $1.07 | $1.58 |
| Resistance Level | $1.29 | $2.12 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 43.68 | 80.41 |
Price Performance
Historical ComparisonAbout DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.